Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session
Portfolio Pulse from Lara Goldstein
Sunstone Therapies' Phase 2 study of COMPASS Pathways' synthetic psilocybin COMP360 showed positive long-term follow-up data in cancer patients with Major Depressive Disorder (MDD). 57% of patients sustained remission of depression, and 64% had a robust clinical response at 18 months after a single 25mg psilocybin dose paired with psychological support.
May 26, 2023 | 10:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
COMPASS Pathways' synthetic psilocybin COMP360 showed positive long-term results in a Phase 2 study for cancer patients with MDD, potentially opening the door to wider adoption of psilocybin therapy.
The positive long-term follow-up data from the Phase 2 study of COMPASS Pathways' synthetic psilocybin COMP360 in cancer patients with MDD is a strong indicator of the potential success of the therapy. This could lead to wider adoption of psilocybin therapy and increased demand for COMP360, positively impacting COMPASS Pathways' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100